Literature DB >> 24336172

The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Elena Herrera-Carrillo1, Ying Poi Liu1, Ben Berkhout2.   

Abstract

RNA interference (RNAi) is highly effective in inhibiting human immunodeficiency virus type 1 (HIV-1) replication by the expression of antiviral short hairpin RNA (shRNA) in stably transduced T-cell lines. For the development of a durable gene therapy that prevents viral escape, we proposed to combine multiple shRNAs against highly conserved regions of the HIV-1 RNA genome. The future in vivo application of such a gene therapy protocol will reach only a fraction of the T cells, such that HIV-1 replication will continue in the unmodified T cells, thereby possibly frustrating the therapy by generation of HIV-1 variants that escape from the inhibition imposed by the protected cells. We studied virus inhibition and evolution in pure cultures of shRNA-expressing cells versus mixed cell cultures of protected and unprotected T cells. The addition of the unprotected T cells indeed seems to accelerate HIV-1 evolution and escape from a single shRNA inhibitor. However, expression of three antiviral shRNAs from a single lentiviral vector prevents virus escape even in the presence of unprotected cells. These results support the idea to validate the therapeutic potential of this anti-HIV approach in appropriate in vivo models.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24336172      PMCID: PMC3944328          DOI: 10.1038/mt.2013.280

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

2.  Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors.

Authors:  Fatima Boutimah; Julia J M Eekels; Ying Poi Liu; Ben Berkhout
Journal:  Antiviral Res       Date:  2013-02-21       Impact factor: 5.970

3.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

4.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

5.  Design of HIV vectors for efficient gene delivery into human hematopoietic cells.

Authors:  Priscilla Y Yam; Shulian Li; Jerry Wu; Jun Hu; John A Zaia; Jiing-Kuan Yee
Journal:  Mol Ther       Date:  2002-04       Impact factor: 11.454

6.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.

Authors:  O ter Brake; N Legrand; K J von Eije; M Centlivre; H Spits; K Weijer; B Blom; B Berkhout
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

8.  Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition.

Authors:  Olivier ter Brake; Karen 't Hooft; Ying Poi Liu; Mireille Centlivre; Karin Jasmijn von Eije; Ben Berkhout
Journal:  Mol Ther       Date:  2008-01-15       Impact factor: 11.454

Review 9.  Achieving a cure for HIV infection: do we have reasons to be optimistic?

Authors:  Valentin Le Douce; Andrea Janossy; Houda Hallay; Sultan Ali; Raphael Riclet; Olivier Rohr; Christian Schwartz
Journal:  J Antimicrob Chemother       Date:  2012-02-01       Impact factor: 5.790

10.  Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1.

Authors:  Mireille Centlivre; Nicolas Legrand; Sofieke Klamer; Ying Poi Liu; Karin Jasmijn von Eije; Martino Bohne; Esther Siteur-van Rijnstra; Kees Weijer; Bianca Blom; Carlijn Voermans; Hergen Spits; Ben Berkhout
Journal:  Mol Ther Nucleic Acids       Date:  2013-09-03       Impact factor: 10.183

View more
  7 in total

1.  Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.

Authors:  Renier Myburgh; Sandra Ivic; Michael S Pepper; Gustavo Gers-Huber; Duo Li; Annette Audigé; Mary-Aude Rochat; Vincent Jaquet; Stephan Regenass; Markus G Manz; Patrick Salmon; Karl-Heinz Krause; Roberto F Speck
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

2.  The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.

Authors:  E Herrera-Carrillo; B Berkhout
Journal:  Gene Ther       Date:  2015-02-26       Impact factor: 5.250

Review 3.  Bone Marrow Gene Therapy for HIV/AIDS.

Authors:  Elena Herrera-Carrillo; Ben Berkhout
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

4.  Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection.

Authors:  Elena Herrera-Carrillo; Ben Berkhout
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

Review 5.  Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies.

Authors:  Gilles Darcis; Atze T Das; Ben Berkhout
Journal:  Viruses       Date:  2018-03-29       Impact factor: 5.048

6.  CRISPR-Cas13a Inhibits HIV-1 Infection.

Authors:  Lijuan Yin; Fei Zhao; Hong Sun; Zhen Wang; Yu Huang; Weijun Zhu; Fengwen Xu; Shan Mei; Xiaoman Liu; Di Zhang; Liang Wei; Shan Cen; Siqi Hu; Chen Liang; Fei Guo
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-01       Impact factor: 8.886

7.  Influence of a 3' Terminal Ribozyme on AgoshRNA Biogenesis and Activity.

Authors:  Elena Herrera-Carrillo; Zongliang Gao; Ben Berkhout
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.